Effects of the atypical antipsychotic clozapine on insulin release in vitro

Neuroendocrinology Letters

Volumn 28, Issue 6, 2007, Pages 854-860

  Melkersson, Kristina ^a   Jansson, Eva ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antipsychotic agents; Clozapine; In vitro; Insulin; Side effect

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; GLUCOSE; INSULIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; IN VITRO STUDY; INCUBATION TIME; INSULIN RELEASE; MALE; METABOLIC DISORDER; NONHUMAN; PANCREAS ISLET CELL; RAT;

EID: 37849041094     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al (1999). Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry. 156: 1686-1696.
2. Ammon HPT, Orci L, Steinke J (1973). Effect of chlorpromazine (CPZ) on insulin release in vivo and in vitro in the rat. J Pharmacol Exp Ther. 187: 423-429.
3. Ardizzone TD, Bradley RJ, Freeman AM, Dwyer DS (2001). Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res. 923: 82-90.
4. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM (1993). Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology. 9: 117-124.
5. Best L, Yates AP, Reynolds GP (2005). Actions of antipsychotic drugs on pancreatic β-cell function: contrasting effects of clozapine and haloperidol. J Psychopharmacol. 19: 597-601.
6. Brambilla F, Guerrini A, Guastalla A, Rovere C, Riggi F (1975). Neuroendocrine effects of haloperidol therapy in chronic schizophrenia. Psychopharmacologia. 44: 17-22.
7. Catanese VM, Kahn CR (2001). Secondary forms of diabetes mellitus. In: Becker KL, editor. Principles and Practice of Endocrinology and Metabolism. Philadelphia, PA: Lippincott Williams and Wilkins. p. 1327-1336.
8. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B (2001). Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. Am J Psychiatry. 158: 518-526.
9. De Vos A, Heimberg H, Quartier E, Huypens P, Bouwens L, Pipeleers D, et al (1995). Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression. J Clin Invest. 96: 2489-2495.
10. El-Denshary ESM, Ismail NA, Montague W (1977). Effects of chlorpromazine on isolated rat islets of Langerhans. Horm Metab Res. 9: 95.
11. El-Denshary ESM, Montague W (1976). Effects of drugs on glucose and tolbutamide-stimulated insulin release from isolated rat islets of Langerhans. Biochem Pharmacol. 25: 1451-1454.
12. Feldman JM, Quickel KE, Lebovitz HE (1972). Potentiation of insulin secretion in vitro by serotonin antagonists. Diabetes. 21: 779-788.
13. Fitton A, Heel RC (1990). Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia [review]. Drugs. 40: 722-747.
14. Gardiner TH, Lewis JM, Shore PA (1978). Distribution of clozapine in the rat: Localization in lung. J Pharmacol Exp Ther. 206: 151-157.
15. Grant AM, Christie MR, Ashcroft SJH (1980). Insulin release from human pancreatic islets in vitro. Diabetologia. 19: 114-117.
16. Guarner V, Hernandez EH, Huerto R, Gorostiza P, Valenzuela F (1993). Trifluoperazine inhibition of insulin-induced increase in skeletal muscle glucose uptake. Eur J Pharmacol. 237: 139-141.
17. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al (2000). Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 157: 975-981.
18. Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, et al (2005). Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: Results of a 10-year naturalistic study. J Clin Psychiatry. 66: 1116-1121.
19. Herbert V, Lau K-S, Gottlieb CW, Bleicher SJ (1965). Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab. 25: 1375-1384.
20. Hermansen K (1978). Haloperidol, a dopaminergic antagonist: Somatostatin-like inhibition of glucagon and insulin release from the isolated, perfused canine pancreas. Diabetologia. 15: 343-347.
21. Johnson DE, Yamazaki H, Ward KM, Schmidt AW, Lebel WS, Treadway JL, et al (2005). Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets. Role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes. 54: 1552-1558.
22. m glucose transporters in noninsulin-dependent diabetes. Science. 250: 546-549. [Erratum in: Science. 1990;250:1195].
23. Jones PM, Persaud SJ (1998). Protein kinases, protein phosphorylation, and the regulation of insulin secretion from pancreatic β-cells [review]. Endocr Rev. 19: 429-461.
24. Joost HG (1979). Inhibition of insulin secretion from the perfused pancreas of the rat by pizotifen. Br J Pharmacol. 67: 265-267.
25. Joost HG, Göke B, Hasselblatt A (1983). Effects of pimozide and apomorphine on insulin secretion from the perfused rat pancreas. Arch Int Pharmacodyn. 263: 155-163.
26. Jori A, Carrara MC (1966). On the mechanism of hyperglycaemic effect of chlorpromazine [letter]. J Pharm Pharmacol. 18: 623-624.
27. MacDonald PE, El-kholy W, Riedel MJ, Salapatek AMF, Light PE, Wheeler MB (2002). The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion [review]. Diabetes. 51 (suppl. 3): S434-442.
28. McClenaghan NH, Flatt PR (1999). Physiological and pharmacological regulation of insulin release: insights offered through exploitation of insulin-secreting cell lines [review]. Diabetes Obes Metab. 1: 137-150.
29. McEvoy JP, Lieberman JA, Scott Stroup T, Davis SM, Meltzer HY, Rosenheck RA, et al (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 163: 600-610.
30. Meier JJ, Butler PC (2006). Insulin secretion. In: DeGroot LJ, Jameson JL, editors. Endocrinology. 5th ed. Philadelphia, PA: Elsevier Saunders. p. 961-973.
31. Melkersson K (2004). Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol. 14: 115-119.
32. Melkersson K, Dahl M-L (2003). Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology. 170: 157-166.
33. Melkersson K, Dahl M-L (2004). Adverse metabolic effects associated with atypical antipsychotics. Literature review and clinical implications [review]. Drugs. 64: 701-723.
34. Melkersson K, Hulting A-L (2001). Insulin and leptin levels in patients with schizophrenia or related psychoses - a comparison between different antipsychotic agents. Psychopharmacology 154: 205-212.
35. Melkersson K, Jansson E (2005). The atypical antipsychotics quetiapine, risperidone and ziprasidone do not increase insulin release in vitro. Neuroendocrinol Lett. 26: 205-208.
36. Melkersson K, Hulting A-L, Brismar K (1999). Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry. 60: 783-791.
37. Melkersson K, Khan A, Hilding A, Hulting A-L (2001). Different effects of antipsychotic drugs on insulin release in vitro. Eur Neuropsychopharmacol. 11: 327-332.
38. Nakadate T, Kubota K, Nakaki T, Kato B (1982). Effect of chlorpromazine on insulin release in mice: comparison between in vivo and in vitro. Jpn J Pharmacol. 32: 950-953.
39. Olefsky JM (1997). Insulin resistance. In: Porte D, Sherwin RS, editors. Diabetes mellitus. 5th ed. Stamford, CT: Appleton and Lange. p. 513-552.
40. Perry PJ, Miller DD, Arndt SV, Cadoret RJ (1991). Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry. 148: 231-235.
41. Rafaelsen OJ (1961). Action of phenothiazine derivatives on carbohydrate uptake of isolated rat diaphragm and isolated rat spinal cord. Psychopharmacologia. 2: 185-196.
42. Remington G (2003). Understanding antipsychotic "atypicality": a clinical and pharmacological moving target [review]. J Psychiatry Neurosci. 28: 275-284.
43. Samols E, Stagner JI (1980). Reinterpretation of the effect of haloperidol and ethanol on insulin secretion. Diabetologia. 19: 81-83.
44. Schwarz L, Munoz R (1968). Blood sugar levels in patients treated with chlorpromazine. Am J Psychiatry. 125: 253-255.
45. Sugden MC, Christie MR, Ashcroft SJH (1979). Presence and possible role of calcium-dependent regulator (calmodulin) in rat islets of Langerhans. FEBS Lett. 105: 95-100.
46. Sussman KE, Pollard HB, Leitner JW, Nesher R, Adler J, Cerasi E (1983). Differential control of insulin secretion and somatostatin-receptor recruitment in isolated pancreatic islets. Biochem J. 214: 225-230.
47. Sutton B, Peters M, McShane P, Gray DW, Morris PJ (1986). Isolation of rat pancreatic islets by ductal injection of collagenase. Transplantation. 42: 689-691.
48. Thonnard-Neumann E (1968). Phenothiazines and diabetes in hospitalized women. Am J Psychiatry. 124: 978-982.
49. Wagstaff AJ, Bryson HM (1995). Clozapine. A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents [review). CNS Drugs. 4: 370-400.
50. Woods SC, Kaiyala K, Porte D, Schwartz MW (1997). Food intake and energy balance. In: Porte D, Sherwin RS, editors. Diabetes mellitus. 5th ed. Stamford, CT: Appleton and Lange. p. 175-192.
51. Yasuda H, Suzuki S, Sawada S, Kanasawa Y, Yamaguchi K, Kume S, et al (1989). Stimulative effects of TMB-8 and trifluoperazine on pancreatic hormone release. Diab Res Clin Prac. 6: 227-232.
52. Yazici KM, Erbas T, Yazici AH (1998). The effect of clozapine on glucose metabolism. Exp Clin Endocrinol Diabetes. 106: 475-477.